Table 2 Oligos used in the studies.
Target site | Application | Forward oligo (5′ > 3′) | Reverse oligo (5′ > 3′) |
|---|---|---|---|
mNap1l3* | qPCR | ||
mHprt1** | qPCR | ||
hNAP1L3 | qPCR | ACCAGAGGTGAAAGCTGAA | CCTGGGGGACTTCTTTAGGA |
hUBC | qPCR | CTGGAAGATGGTCGTACCCTG | GGTCTTGCCAGTGAGTGTCT |
hHOXA3 | qPCR | CTCCAGCTCAGGCGAAAG | ACAGGTAGCGGTTGAAGTGG |
hHOXA4 | qPCR | CATGTCAGCGCCGTTAACC | ACCTGCTGCCGGGTGTAG |
hHOXA5 | qPCR | CGCCCAACCCCAGATCTAC | CCGCCTATGTTGTCATGACTTATG |
hHOXA6 | qPCR | CGCGGGTGCTGTGTATG | CCTTCTCCAGCTCCAGTGTC |
hHOXA9 | qPCR | CCCCATCGATCCCAATAACC | CCAGGGTCTGGTGTTTTGTATAGG |
hCDK1 | qPCR | GGAAACCAGGAAGCCTAGCA | GATCATAGATTAACATTTTCGAGAGCAA |
mNAP1l3 | OE cloning | ANGCTCTAGAATGGCAGAAGCGGATCCTAAAATG | ANGCGCGGCCGCCTACTTGTAGTACTTCCTATTT CATAAT |
mNAP1l3 | CRISPR gRNA | ACCGGCGCCTCTTCAGCAACCCCAT | AAACATGGGGTTGCTGAAGAGGCGC |
mNAP1l3 | PCR mutation analysis | CCACAGCTGCTGCAGTCC | GCCCTTCTGGAAGGCTCAG |
mNAP1l3 | Sequencing mutation analysis | CAGTCCGTGTTGCCACTG |
